BrainsWay Ltd. reported second quarter 2026 financial results and raised full-year guidance. Revenue increased 35% to $17.1 million, while Adjusted EBITDA more than doubled year-over-year to $3.5 million with a 20% margin. The company shipped a record 125 Deep TMS systems in Q2, bringing the total installed base to approximately 1,949 units. Remaining performance obligations grew 30% to $80.4 million. Management raised FY 2026 revenue guidance to $68–$70 million and Adjusted EBITDA guidance to $13–$14 million. BrainsWay Ltd. operates in the medical device industry, developing noninvasive neurostimulation treatments for mental health disorders.

BrainsWay Ltd. announced a $3 million minority equity investment in Radial Health, Inc., a management services organization supporting a network of Brain Medicine clinics. The investment was made as part of Radial's Series A financing, joining other investors such as General Catalyst and Floating Point Capital. BrainsWay's strategic initiative is to secure minority equity positions in high-performing mental health provider networks to expand access to noninvasive mental health treatment. BrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders.

BrainsWay presented positive data from its largest real-world study regarding Deep TMS™ usage in patients presenting with comorbid Post-Traumatic Stress Disorder (PTSD) and Major Depressive Disorder (MDD). BrainsWay Ltd. is a medical device company that develops and manufactures non-invasive neuromodulation technologies.

BrainsWay reported that its Accelerated Deep TMS™ technology now covers over 57 million lives. This coverage expansion reflects favorable media and industry reporting regarding the technology's reach. BrainsWay is a medical device company specializing in neuromodulation technologies.

BrainsWay presented 12-month durability data for its SWIFT Accelerated Deep TMS at the Clinical TMS Society Annual Meeting. The company operates in the medical device industry, providing non-invasive brain stimulation treatments for neurological and psychiatric disorders.